| Literature DB >> 33741711 |
Robert Kupp1, Lisa Ruff1, Sabrina Terranova1, Erica Nathan1, Stephane Ballereau1, Rory Stark1, Chandra Sekhar Reddy Chilamakuri1, Nadin Hoffmann1, Katherine Wickham-Rahrmann1, Marcus Widdess1, Amir Arabzade2, Yanhua Zhao2, Srinidhi Varadharajan2, Tuyu Zheng3, Mohankumar Murugesan4, Stefan M Pfister3, Daisuke Kawauchi5, Kristian W Pajtler3, Benjamin Deneen6, Stephen C Mack2, Katherine E Masih7, Berkley E Gryder7, Javed Khan7, Richard J Gilbertson8,9.
Abstract
ZFTA (C11orf95)-a gene of unknown function-partners with a variety of transcriptional coactivators in translocations that drive supratentorial ependymoma, a frequently lethal brain tumor. Understanding the function of ZFTA is key to developing therapies that inhibit these fusion proteins. Here, using a combination of transcriptomics, chromatin immunoprecipitation sequencing, and proteomics, we interrogated a series of deletion-mutant genes to identify a tripartite transformation mechanism of ZFTA-containing fusions, including: spontaneous nuclear translocation, extensive chromatin binding, and SWI/SNF, SAGA, and NuA4/Tip60 HAT chromatin modifier complex recruitment. Thereby, ZFTA tethers fusion proteins across the genome, modifying chromatin to an active state and enabling its partner transcriptional coactivators to promote promiscuous expression of a transforming transcriptome. Using mouse models, we validate further those elements of ZFTA-fusion proteins that are critical for transformation-including ZFTA zinc fingers and partner gene transactivation domains-thereby unmasking vulnerabilities for therapeutic targeting. SIGNIFICANCE: Ependymomas are hard-to-treat brain tumors driven by translocations between ZFTA and a variety of transcriptional coactivators. We dissect the transforming mechanism of these fusion proteins and identify protein domains indispensable for tumorigenesis, thereby providing insights into the molecular basis of ependymoma tumorigenesis and vulnerabilities for therapeutic targeting.This article is highlighted in the In This Issue feature, p. 2113. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33741711 PMCID: PMC8918067 DOI: 10.1158/2159-8290.CD-20-1052
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272